The ARC Program in the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) aims to speed the development of effective and safe treatments for rare diseases (RD) by leveraging innovative scientific designs and regulatory science resources.
Method
ARC builds on CDER's existing capabilities and expertise to foster engagement and education with the RD community and promotes cross-agency collaboration by strengthening infrastructure to coordinate, facilitate, and support innovative and ongoing RD drug development.
Results
Engagement and Education. ARC’s engagement and education initiatives leverage outreach and expertise in the rare diseases space. In partnership with other FDA subject matter experts (SMEs), ARC has undertaken several initiatives to deepen the understanding of regulatory frameworks and provide more accessible information about CDER RD news to the RD community. These initiatives include:
-The Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative that provides educational resources to aid drug developers and FDA staff navigate the complexities of RD drug development -Conferences and workshops that foster an exchange of experiences, challenges, and insights -ARC Annual Reports, newsletters, website, and social media platform
Scientific and Regulatory Innovation. The ARC Program supports various scientific and regulatory initiatives intended to provide direction and to drive the innovative development of various supporting tools to promote RD drug development: -The Translational Science Team (TST)-a group of SMEs and senior leaders focused on supporting review teams within CDER -RD Drug Development Design (RD4)-Expanded efforts to address challenges in small population trial design and analyses including the use of fit-for-purpose statistical methods -Joint CDER and Center for Biologics Review and Evaluation (CBER) programs including the Rare Disease Endpoint Advancement (RDEA) Pilot Program and the Support for clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program
Collaborations. ARC shares learnings from new CDER initiatives such as the Quantitative Medicine Center of Excellence, the CDER Center for Clinical Trial Innovation (C3TI), and the CDER Center for Real-World Evidence Innovation with other FDA Centers/Offices through the Rare Disease Innovation Hub.
Conclusion
With great intention, ARC has and will continue to balance the needs of building strong foundations in regulatory science, education, and engagement to support the RD community while exploring continuous improvement and innovation in understanding and developing safe and effective drug therapies for rare diseases. ARC builds on CDER's existing capabilities and expertise, bridging the gap between the needs of patients and the complexities of RD drug development. The ARC Program is eager to enhance collaboration and drive greater progress. ARC will continue to empower FDA staff and the RD community to innovate and navigate the complexities of RD drug development with scientific rigor and fit-for-purpose approaches, ultimately improving outcomes and options for people living with RDs. Successful drug development relies on our ability to unite regulatory considerations with scientific advancements, early-stage planning, and strategic partnerships. Recognizing that a collective effort is key to driving meaningful change, the ARC Program aims to accelerate the path toward delivering safe and effective treatments for RDs.
